• There was no association between genome-wide or C5-related gene variants and C5 levels; plasma CRP and C5 showed a linear relationship.

  • Increased levels of C5 were positively associated with future venous thromboembolic events in a nested case-control study.

The role of complement in the pathogenesis of venous thromboembolism (VTE) is unclear. We wanted to investigate (1) whether plasma complement component C5 (C5) levels are influenced by genetic variants or chronic inflammation and (2) the association between plasma C5 and risk of future VTE in a nested case-control study of 415 patients with VTE and 848 age- and sex-matched controls derived from the Tromsø Study. Plasma C5 levels were measured at inclusion. Odds ratios (ORs) with 95% confidence intervals (95% CIs) for provoked and unprovoked VTE across tertiles of C5 concentrations were estimated by logistic regression. Adjustment for C-reactive protein (CRP) served as a proxy for general inflammation. Whole-exome sequencing and protein quantitative trait loci analyses were performed to assess genetic influence on C5 concentrations. There was no association between genome-wide or C5-related gene variants and C5 levels. The association between plasma C5 levels and VTE risk displayed a threshold effect, where subjects with C5 levels above the lowest tertile had increased risk of VTE. Subjects in tertile 3 (highest C5 levels) had an age- and sex-adjusted OR of 1.45 (95% CI, 1.07-1.96) compared with tertile 1 (lowest). These statistics were more pronounced for unprovoked VTE (OR, 1.70; 95% CI, 1.11-2.60). Adjustments for body mass index and CRP had minor impact on risk estimates. The OR increased substantially with shorter time between blood sampling and VTE event. In conclusion, plasma C5 was associated with risk of future VTE. C5 levels were not genetically regulated and were only slightly influenced by chronic inflammation.

1.
Arshad
N
,
Bjøri
E
,
Hindberg
K
,
Isaksen
T
,
Hansen
JB
,
Braekkan
SK
.
Recurrence and mortality after first venous thromboembolism in a large population-based cohort
.
J Thromb Haemost.
2017
;
15
(
2
):
295
-
303
.
2.
Prandoni
P
,
Lensing
AW
,
Cogo
A
, et al
.
The long-term clinical course of acute deep venous thrombosis
.
Ann Intern Med.
1996
;
125
(
1
):
1
-
7
.
3.
Wolberg
AS
,
Rosendaal
FR
,
Weitz
JI
, et al
.
Venous thrombosis
Nat Rev Dis Primer.
2015
;
1
:
15006
.
4.
Mackman
N
.
New insights into the mechanisms of venous thrombosis
.
J Clin Invest.
2012
;
122
(
7
):
2331
-
2336
.
5.
Foley
JH
,
Conway
EM
.
Cross talk pathways between coagulation and inflammation
.
Circ Res.
2016
;
118
(
9
):
1392
-
1408
.
6.
Ekdahl
KN
,
Teramura
Y
,
Hamad
OA
, et al
.
Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation
.
Immunol Rev.
2016
;
274
(
1
):
245
-
269
.
7.
Nørgaard
I
,
Nielsen
SF
,
Nordestgaard
BG
.
Complement C3 and high risk of venous thromboembolism: 80517 individuals from the Copenhagen General Population Study
.
Clin Chem.
2016
;
62
(
3
):
525
-
534
.
8.
Høiland
II
,
Liang
RA
,
Braekkan
SK
, et al
.
Complement activation assessed by the plasma terminal complement complex and future risk of venous thromboembolism
.
J Thromb Haemost.
2019
;
17
(
6
):
934
-
943
.
9.
Liang
RA
,
Høiland
II
,
Ueland
T
, et al
.
Plasma levels of mannose-binding lectin and future risk of venous thromboembolism
J Thromb Haemost.
2019
;
17
(
10
):
1661
-
1669
.
10.
Morgan
BP
.
The complement system: an overview
.
Methods Mol Biol.
2000
:
150
:
1
-
13
.
11.
Hillmen
P
,
Muus
P
,
Röth
A
, et al
.
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
.
Br J Haematol.
2013
;
162
(
1
):
62
-
73
.
12.
Kilgore
KS
,
Schmid
E
,
Shanley
TP
, et al
.
Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation
.
Am J Pathol.
1997
;
150
(
6
):
2019
-
2031
.
13.
Ando
B
,
Wiedmer
T
,
Hamilton
KK
,
Sims
PJ
.
Complement proteins C5b-9 initiate secretion of platelet storage granules without increased binding of fibrinogen or von Willebrand factor to newly expressed cell surface GPIIb-IIIa
.
J Biol Chem.
1988
;
263
(
24
):
11907
-
11914
.
14.
Wiedmer
T
,
Esmon
CT
,
Sims
PJ
.
Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase
.
Blood.
1986
;
68
(
4
):
875
-
880
.
15.
Sims
PJ
,
Faioni
EM
,
Wiedmer
T
,
Shattil
SJ
.
Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity
.
J Biol Chem.
1988
;
263
(
34
):
18205
-
18212
.
16.
Tedesco
F
,
Pausa
M
,
Nardon
E
,
Introna
M
,
Mantovani
A
,
Dobrina
A
.
The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity
.
J Exp Med.
1997
;
185
(
9
):
1619
-
1627
.
17.
Hattori
R
,
Hamilton
KK
,
McEver
RP
,
Sims
PJ
.
Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface
.
J Biol Chem.
1989
;
264
(
15
):
9053
-
9060
.
18.
Ikeda
K
,
Nagasawa
K
,
Horiuchi
T
,
Tsuru
T
,
Nishizaka
H
,
Niho
Y
.
C5a induces tissue factor activity on endothelial cells
.
Thromb Haemost.
1997
;
77
(
2
):
394
-
398
.
19.
Landsem
A
,
Fure
H
,
Krey Ludviksen
J
, et al
.
Complement component 5 does not interfere with physiological hemostasis but is essential for Escherichia coli-induced coagulation accompanied by Toll-like receptor 4
.
Clin Exp Immunol.
2019
;
196
(
1
):
97
-
110
.
20.
Subramaniam
S
,
Jurk
K
,
Hobohm
L
, et al
.
Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development
Blood.
2017
;
129
(
16
):
2291
-
2302
.
21.
Jacobsen
BK
,
Eggen
AE
,
Mathiesen
EB
,
Wilsgaard
T
,
Njølstad
I
.
Cohort profile: the Tromso Study
.
Int J Epidemiol.
2012
;
41
(
4
):
961
-
967
.
22.
Braekkan
SK
,
Borch
KH
,
Mathiesen
EB
,
Njølstad
I
,
Wilsgaard
T
,
Hansen
JB
.
Body height and risk of venous thromboembolism: the Tromsø Study
.
Am J Epidemiol.
2010
;
171
(
10
):
1109
-
1115
.
23.
Carson
AR
,
Smith
EN
,
Matsui
H
, et al
.
Effective filtering strategies to improve data quality from population-based whole exome sequencing studies
.
BMC Bioinformatics.
2014
;
15
(
1
):
125
.
24.
Solomon
T
,
Smith
EN
,
Matsui
H
, et al;
INVENT Consortium
.
Associations between common and rare exonic genetic variants and serum levels of 20 cardiovascular-related proteins: the Tromsø Study
.
Circ Cardiovasc Genet.
2016
;
9
(
4
):
375
-
383
.
25.
Hutcheon
JA
,
Chiolero
A
,
Hanley
JA
.
Random measurement error and regression dilution bias
.
BMJ.
2010
;
340
(
2
):
c2289
.
26.
Kang
HM
,
Sul
JH
,
Service
SK
, et al
.
Variance component model to account for sample structure in genome-wide association studies
.
Nat Genet.
2010
;
42
(
4
):
348
-
354
.
27.
Wyatt
RJ
,
Bridges
RB
,
Halatek
DG
.
Complement levels in cigarette smokers: elevation of serum concentrations of C5, C9, and C1-inhibitor
.
J Clin Lab Immunol.
1981
;
6
(
2
):
131
-
135
.
28.
Ritis
K
,
Doumas
M
,
Mastellos
D
, et al
.
A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways
J Immunol..
2006
;
177
(
7
):
4794
-
4802
.
29.
Kilgore
KS
,
Shen
JP
,
Miller
BF
,
Ward
PA
,
Warren
JS
.
Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1
.
J Immunol.
1995
;
155
(
3
):
1434
-
1441
.
30.
Campello
E
,
Spiezia
L
,
Radu
CM
, et al
.
Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism
.
Thromb Res.
2011
;
127
(
5
):
473
-
477
.
31.
Wakefield
TW
,
Strieter
RM
,
Wilke
CA
, et al
.
Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules
.
Arterioscler Thromb Vasc Biol.
1995
;
15
(
2
):
258
-
268
.
32.
Smith
A
,
Quarmby
JW
,
Collins
M
,
Lockhart
SM
,
Burnand
KG
.
Changes in the levels of soluble adhesion molecules and coagulation factors in patients with deep vein thrombosis
.
Thromb Haemost.
1999
;
82
(
6
):
1593
-
1599
.
33.
Gao
C
,
Xie
R
,
Yu
C
, et al
.
Procoagulant activity of erythrocytes and platelets through phosphatidylserine exposure and microparticles release in patients with nephrotic syndrome
.
Thromb Haemost.
2012
;
107
(
4
):
681
-
689
.
34.
Gabay
C
,
Kushner
I
.
Acute-phase proteins and other systemic responses to inflammation
.
N Engl J Med.
1999
;
340
(
6
):
448
-
454
.
35.
Agrawal
A
.
CRP after 2004
.
Mol Immunol.
2005
;
42
(
8
):
927
-
930
.
You do not currently have access to this content.

Sign in via your Institution

Sign In